Supplemental Materials, Figures 1 - 4, Tables 1 - 4 from Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

Fig. S1. CARTmeso cell manufacturing and treatment schedules. Fig. S2. Detection of human anti-chimeric antibody responses in patients post-CARTmeso cell infusion. Fig. S3. Serum cytokines and chemokines in PDA patient 21211-101. Fig. S4. CARTmeso cytolytic activity against allogeneic and autologous pancreatic cancer cell lines Table S1. Patient demographics. Table S2. Treatment-related adverse events. Table S3. Protoarray analysis of serum samples from mesothelioma patient 17510-105 Table S4. Protoarray analysis of serum samples from pancreatic cancer patient 21211-101